Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06014541 · ClinicalTrials.gov registry record
Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
A clinical trial of Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome, sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- 29
- Enrollment target
- 5
- Study locations
NCT06014541 is a study of Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 29 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT06014541, a study of Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome, is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to prospectively assess longitudinal changes in biomarkers (MECP2, potential biomarkers of target engagement and disease activity) in cerebrospinal fluid (CSF) and blood; characterize longitudinal changes in performance on clinical scales (clinician-reported measures of neurodevelopment and functioning) and caregiver-reported outcome assessments (communication, gastrointestinal, social-emotional-adaptive behavioral measures); evaluate longitudinal changes in caregiver-reported health-related quality-of-life measures; and assess the frequency, type, and severity of seizures over time.
Conditions Studied
Study Locations (5)
California
- UCSD - Rady Children's Hospital - San Diego
Minnesota
- Gillette Children's Specialty Healthcare - Saint Paul
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06014541
The ClinicalTrials.gov registry entry for NCT06014541 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT06014541 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06014541 about?
NCT06014541 is a clinical study titled "Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome". The purpose of the study is to prospectively assess longitudinal changes in biomarkers (MECP2, potential biomarkers of target engagement and disease activity) in cerebrospinal fluid (CSF) and blood; characterize longitudinal changes in performance on clinical scales (clinician-reported measures of n...
What is the current status of trial NCT06014541?
This trial is currently active not recruiting. The enrollment target is 29 participants. The study started on 2023-10-03. Estimated completion is 2026-06.
What conditions does trial NCT06014541 study?
This clinical trial studies the following conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome.
Who is sponsoring clinical trial NCT06014541?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06014541 being conducted?
This trial has 5 study locations across California, Minnesota, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.